Oura prepares for a $15.6 billion Nasdaq IPO, leveraging 121% subscription growth and strategic partnerships with Eli Lilly and Dexcom to position itself as a critical biometric data layer in clinical metabolic healthcare.
Oura's IPO targets a $15.6 billion valuation with 121% subscription revenue growth and positive net income, but heavy insider selling, limited primary proceeds, and a sleep-tracking lawsuit create balanced risk.
Dexcom's Stelo glucose sensor integration into Oura's software expands its continuous-monitoring ecosystem and real-world data use.
Eli Lilly's $100 million IPO order and LillyDirect biometric integration deepen its digital health positioning in GLP-1 treatment monitoring.
Garmin is referenced solely as a valuation comparison at 7.5x sales versus Oura's 9.7x, with no direct event impact.
Apple is used only as a comparable at roughly 12x sales to frame Oura's valuation, with no impact on Apple itself.
Robinhood is mentioned as a retail access point for Oura's IPO, implying possible trading volume but no material fundamental impact.
Oura is set to debut on the Nasdaq with a valuation of up to $15.6 billion, offering 50 million shares priced between $40 and $44. The company has successfully pivoted from a hardware-focused wearable to a high-growth subscription model, reporting 121% year-over-year software revenue growth and positive net income. Institutional support is anchored by Eli Lilly, which has signaled interest in a $100 million stake to bolster its digital health and GLP-1 monitoring ecosystem.
Oura is being valued as a high-growth health intelligence platform rather than a traditional hardware maker, supported by 121% subscription revenue growth and deep integration into clinical workflows like GLP-1 monitoring.
The integration of Dexcom's Stelo glucose sensor into Oura's software creates a two-way feedback loop, allowing users to correlate nutritional spikes with physiological recovery data, further cementing Oura's role in metabolic health.